Key result
Vagus Nerve Stimulation combined with treatment-as-usual showed superior antidepressant effects vs treatment-as-usual alone, with maximal benefit after 12 months.
Why the study?
The Vagus Nerve Stimulation Therapy System has been studied for over 20 years in difficult-to-treat depression, and this review distills implications for future therapeutic trials in this population.
Does Vagus Nerve Stimulation improve symptoms in patients with difficult-to-treat depression?
Does Vagus Nerve Stimulation improve symptoms in patients with difficult-to-treat depression?
This is the authors' abstract. We don't add key points for this paper.
PURPOSE: The Vagus Nerve Stimulation (VNS) Therapy System has been studied for more than 20 years in patients with severe, treatment-resistant, chronic mood disorder, i.e., difficult-to-treat depression (DTD). This review distills some of the implications of this research for future therapeutic trials in this population. METHODS: A narrative review is provided on VNS in DTD. Protocols for a new, large, sham-controlled trial and a global, longitudinal observational study are described. RESULTS: Following encouraging results in open studies, a randomized, masked, sham-controlled trial of VNS for DTD failed to demonstrate an effect on the primary outcome. The negative results may have been partly due to inadequate treatment duration (10 weeks). In long-term observational studies, adjunctive VNS, combined with treatment-as-usual (VNS+TAU), was administered to more than 1100 DTD patients and compared with TAU alone in more than 400 patients. VNS+TAU had superior antidepressant effects, but maximal symptom reduction was often observed after 12 months or longer of stimulation. VNS+TAU had also marked superiority in durability of benefit. Sustained levels of symptom reduction below the traditional cutoff for response (i.e. < 50%) were associated with improved quality of life. LIMITATIONS: Most comparisons of VNS+TAU and TAU were derived from observational, open label studies. CONCLUSION: The history of VNS in DTD has implications for interventional studies in this population, and perhaps other chronic medical disorders. The slow onset of benefit with VNS necessitates considerably longer controlled observation periods to establish efficacy. Durability of benefit should be routinely incorporated in efficacy assessment. New outcome metrics are needed to both categorically identify clinically meaningful benefit and to integrate information on symptom burden over time.
Vagus nerve stimulation for difficult-to-treat depression requires long-term observation (≥12 months) to establish efficacy and durability of benefit.
No takes yet. Share an insight, caveat, or question.
Sackeïm et al. (2020) conducted a review in Difficult-to-treat depression (DTD). Vagus Nerve Stimulation (VNS) vs. Treatment-as-usual (TAU) was evaluated. Vagus Nerve Stimulation combined with treatment-as-usual showed superior antidepressant effects vs treatment-as-usual alone, with maximal benefit after 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: